MRI对乳腺癌药物治疗所致心脏毒性的早期检测  

Early Detection of MRI Cardiac Toxicity Caused by the Treatment of Breast Cancer Drugs

作　　者：王滕[1,2] 王翠艳 

机构地区：[1]山东大学,山东 济南 [2]山东省立医院放射科,山东 济南

出　　处：《临床医学进展》2023年第3期4726-4733,共8页Advances in Clinical Medicine

摘　　要：有数据显示,乳腺癌已占据女性癌症发病率和死亡率的首位,但得益于医疗水平的进步,患者的生存时间整体延长。然而代价是心脏毒性和心功能不全的风险增加,有必要引起医生足够的警惕和重视。心脏磁共振(Cardiac Magnetic Resonance, CMR)可显示心脏的结构、功能及心肌组织特征,其先进的测量应变及mapping技术可早期发现心肌损伤,包括心肌水肿、纤维化及亚临床心肌功能改变等。总之心脏MRI可早期发现乳腺癌治疗所致心脏毒性,并对后续的监测、疗效评估及预后判断具有重要的临床价值。本文就MRI对乳腺癌药物治疗所致心脏毒性的早期检测作一综述。Some data show that breast cancer has occupied the first place in terms of cancer morbidity and mortality in women, but due to medical advances, patients have an overall longer survival time. The cost, however, is an increased risk of cardiotoxicity and cardiac insufficiency, warranting sufficient vigilance and attention from physicians. Cardiac Magnetic Resonance (CMR) reveals the structure, function, and myocardial tissue characteristics of the heart, and its advanced strain and mapping techniques allow for early detection of myocardial injury, including myocardial edema, fibrosis, and subclinical myocardial functional changes. In conclusion, cardiac MRI can provide early detection of cardiotoxicity due to breast cancer treatment and is clinically important for follow-up monitoring, efficacy assessment, and prognosis. In this paper, we review the early detection of cardiotoxicity due to breast cancer drug therapy by MRI.

关 键 词：磁共振成像 乳腺癌 心脏毒性 化学治疗 靶向治疗 

分 类 号：R73[医药卫生—肿瘤]